Chirag Mehta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chirag Mehta has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Fatima Raza
The Warren Alpert Medical School of Brown University, Providence, USA
2 shared publications- Aneeqah Naeem
Department of Cardiology, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA
1 shared publication - Antony F. Chu
Brown University, Cardiac Electrophysiology , Providence , United States of America
1 shared publication - Aryan Mehta
Department of Medicine University of Connecticut School of Medicine Farmington Connecticut USA
1 shared publication Atin Jindal
Brown University Health
1 shared publicationBraden Vogt
The Warren Alpert Medical School, Brown University Providence Rhode Island USA
1 shared publication
Latest Publications
- Open Access
- 17 February 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (4) , e047049
Cardiogenic Shock Detection Using Electronic Medical Records: A Review and Blueprint for Clinical Implementation and Future Research
Despite advances in drug and device technology, health care delivery, and research infrastructure, cardiogenic shock (CS) continues to have nearly 50% in‐hospital mortality. In patients with CS, both the initial severity of Society for Cardiovascular Angiography and Intervention CS and its subsequent trajectory predicts the clinical outcomes. Accordingly, delayed initial recognition and failure to escalate or deescalate treatment can significantly affect the outcomes of CS. Traditional assessment methods, with the exception of blood pressure measurement, require a high index of suspicion and frequent reassessment by the clinical team. Electronic medical record‐based detection has been successfully implemented in acute and critical care patients with septic shock and acute kidney injury. In CS, electronic medical record‐based studies have largely focused on using models to predict outcomes in patients with CS, with limited data on electronic medical record‐based tools to assist with either predicting CS or providing real time alerts when escalation or de‐escalation might be indicated. Early detection of CS may be associated with detection of earlier Society for Cardiovascular Angiography and Intervention stages of CS and potentially prevent deterioration to higher stages. In this review, we seek to highlight a blueprint for electronic medical record‐based detection of CS that focuses on reproducibility, convenience, clinical decision support, and research aspects.
- 17 February 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (4) , e047049
Open AccessCardiogenic Shock Detection Using Electronic Medical Records: A Review and Blueprint for Clinical Implementation and Future Research
Despite advances in drug and device technology, health care delivery, and research infrastructure, cardiogenic shock (CS) continues to have nearly 50% in‐hospital mortality. In patients with CS, both the initial severity of Society for Cardiovascular Angiography and Intervention CS and its subsequent trajectory predicts the clinical outcomes. Accordingly, delayed initial recognition and failure to escalate or deescalate treatment can significantly affect the outcomes of CS. Traditional assessment methods, with the exception of blood pressure measurement, require a high index of suspicion and frequent reassessment by the clinical team. Electronic medical record‐based detection has been successfully implemented in acute and critical care patients with septic shock and acute kidney injury. In CS, electronic medical record‐based studies have largely focused on using models to predict outcomes in patients with CS, with limited data on electronic medical record‐based tools to assist with either predicting CS or providing real time alerts when escalation or de‐escalation might be indicated. Early detection of CS may be associated with detection of earlier Society for Cardiovascular Angiography and Intervention stages of CS and potentially prevent deterioration to higher stages. In this review, we seek to highlight a blueprint for electronic medical record‐based detection of CS that focuses on reproducibility, convenience, clinical decision support, and research aspects.
- Open Access
- 11 May 2024
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 18 (1) , 1-6
In situ ascending aortic thrombus in a patient with metastatic lung adenocarcinoma and no aortic atherosclerosis or cisplatin exposure: a case report
Background: An ascending aortic thrombus is exceedingly rare. Two instances have been reported in the setting of lung cancer, but only after cisplatin use, which is associated with hypercoagulability. We present the first case of a patient with lung cancer who developed an ascending aortic thrombus without structural risk factors or chemotherapy use. Case: A 60-year-old white female with significant smoking history presented with several weeks of malaise. A chest computed tomography scan revealed a 2.2-cm right upper lobe mass. As an outpatient, right hilar lymph node immunohistochemistry (IHC) samples via endobronchial ultrasound confirmed thyroid transcription factor-1 adenocarcinoma. After the procedure, the patient endorsed dyspnea and was advised to go to the emergency department. A chest computed tomography angiography identified a new 2.4 × 1.1 × 1.1 cm thrombus within the proximal aortic arch. No pulmonary emboli or intrapulmonary shunts were identified. A hypercoagulable workup was negative. Transthoracic echocardiogram was without left ventricular thrombus, akinesis or hypokinesis, left atrial dilation, or intracardiac shunts. A lower extremity ultrasound was negative for deep vein thrombosis. Given the procedural risk, thrombectomy was deferred. The patient was transitioned to enoxaparin, and a repeat computed tomography for resolution is in process. Conclusion: To our knowledge, this is the only case detailing an in situ ascending aortic thrombus in the setting of lung cancer, without structural risk factors, chemotherapy use, or other hypercoagulable comorbidities. Optimal management for an aortic thrombus and malignant disease is less clear. Clinicians should be vigilant for unusual arterial thromboses in patients with high metastatic burden.
- 11 May 2024
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 18 (1) , 1-6
Open AccessIn situ ascending aortic thrombus in a patient with metastatic lung adenocarcinoma and no aortic atherosclerosis or cisplatin exposure: a case report
Background: An ascending aortic thrombus is exceedingly rare. Two instances have been reported in the setting of lung cancer, but only after cisplatin use, which is associated with hypercoagulability. We present the first case of a patient with lung cancer who developed an ascending aortic thrombus without structural risk factors or chemotherapy use. Case: A 60-year-old white female with significant smoking history presented with several weeks of malaise. A chest computed tomography scan revealed a 2.2-cm right upper lobe mass. As an outpatient, right hilar lymph node immunohistochemistry (IHC) samples via endobronchial ultrasound confirmed thyroid transcription factor-1 adenocarcinoma. After the procedure, the patient endorsed dyspnea and was advised to go to the emergency department. A chest computed tomography angiography identified a new 2.4 × 1.1 × 1.1 cm thrombus within the proximal aortic arch. No pulmonary emboli or intrapulmonary shunts were identified. A hypercoagulable workup was negative. Transthoracic echocardiogram was without left ventricular thrombus, akinesis or hypokinesis, left atrial dilation, or intracardiac shunts. A lower extremity ultrasound was negative for deep vein thrombosis. Given the procedural risk, thrombectomy was deferred. The patient was transitioned to enoxaparin, and a repeat computed tomography for resolution is in process. Conclusion: To our knowledge, this is the only case detailing an in situ ascending aortic thrombus in the setting of lung cancer, without structural risk factors, chemotherapy use, or other hypercoagulable comorbidities. Optimal management for an aortic thrombus and malignant disease is less clear. Clinicians should be vigilant for unusual arterial thromboses in patients with high metastatic burden.
- Open Access
- 7 November 2023
- Published by Springer Nature in Research Square
In-Situ Ascending Aortic Thrombus in an Asymptomatic Patient with Metastatic Lung Adenocarcinoma Not On Cisplatin Therapy
Background: An ascending aortic thrombus is exceedingly rare. Two instances have been reported in the setting of lung cancer, but only after cisplatin use, which is associated with hypercoagulability. We present the first case of a patient with lung cancer who developed an ascending aortic thrombus, without structural risk factors or chemotherapy use. Case: A 60-year-old female with a significant smoking history, presented with several weeks of malaise. A CT chest revealed a 2.2 cm right upper lobe mass. As an outpatient, right hilar lymph node IHC samples via EBUS confirmed TTF-1+ adenocarcinoma. After the procedure, the patient endorsed dyspnea and was advised to go to the ED. Decision‐making: A CTA chest identified a new 2.4 x 1.1 x 1.1 cm thrombus within the proximal aortic arch. No PE or intrapulmonary shunts were identified. A hypercoagulable workup was negative. TTE was without LV thrombus, akinesis or hypokinesis, LA dilation, or intracardiac shunts. A lower extremity ultrasound was negative for DVT. Given the procedural risk, thrombectomy was deferred. The patient was transitioned to enoxaparin, and a repeat CT for resolution is in process. Conclusion: To our knowledge, this is the only case detailing an in-situ ascending aortic thrombus in the setting of lung cancer, without structural risk factors, chemotherapy use, or other hypercoagulable comorbidities. Optimal management for an aortic thrombus and malignant disease is less clear. Clinicians should be vigilant for unusual arterial thromboses in patients with high metastatic burden.
- 7 November 2023
- Published by Springer Nature in Research Square
Open AccessIn-Situ Ascending Aortic Thrombus in an Asymptomatic Patient with Metastatic Lung Adenocarcinoma Not On Cisplatin Therapy
Background: An ascending aortic thrombus is exceedingly rare. Two instances have been reported in the setting of lung cancer, but only after cisplatin use, which is associated with hypercoagulability. We present the first case of a patient with lung cancer who developed an ascending aortic thrombus, without structural risk factors or chemotherapy use. Case: A 60-year-old female with a significant smoking history, presented with several weeks of malaise. A CT chest revealed a 2.2 cm right upper lobe mass. As an outpatient, right hilar lymph node IHC samples via EBUS confirmed TTF-1+ adenocarcinoma. After the procedure, the patient endorsed dyspnea and was advised to go to the ED. Decision‐making: A CTA chest identified a new 2.4 x 1.1 x 1.1 cm thrombus within the proximal aortic arch. No PE or intrapulmonary shunts were identified. A hypercoagulable workup was negative. TTE was without LV thrombus, akinesis or hypokinesis, LA dilation, or intracardiac shunts. A lower extremity ultrasound was negative for DVT. Given the procedural risk, thrombectomy was deferred. The patient was transitioned to enoxaparin, and a repeat CT for resolution is in process. Conclusion: To our knowledge, this is the only case detailing an in-situ ascending aortic thrombus in the setting of lung cancer, without structural risk factors, chemotherapy use, or other hypercoagulable comorbidities. Optimal management for an aortic thrombus and malignant disease is less clear. Clinicians should be vigilant for unusual arterial thromboses in patients with high metastatic burden.
- Open Access
- 30 October 2023
- Published by Open Exploration Publishing in Exploration of Medicine
- Vol. 4 (5) , 772-781
Contemporary review: recognition, management, and screening for radiation-induced heart disease
Radiation is a primary therapy in the treatment of thoracic malignancies with clear survival benefits. Consequently, patients with cancer are living longer but may be subject to a wide array of cardiotoxic effects from collateral radiation damage. Ensuing fibrosis can affect any portion of the cardiac parenchyma, increasing the risk for accelerated coronary artery disease, pericardial sequelae such as constrictive pericarditis, valvulopathy, restrictive cardiomyopathy, and a myriad of conduction system abnormalities. Unfortunately, the effects of cardiotoxicity can be subclinical or delayed and there remains an unmet need to standardize management strategies for these patients. Based on current data, it is prudent to consider percutaneous approaches first for coronary and valvular disease and traditional, supportive measures for the remaining sequelae. Every attempt should be made to undergo a complete operative haul due to the increased risks of re-operation if surgery is to be performed. Surrounding the patient with a multidisciplinary heart team is critical.
- 30 October 2023
- Published by Open Exploration Publishing in Exploration of Medicine
- Vol. 4 (5) , 772-781
Open AccessContemporary review: recognition, management, and screening for radiation-induced heart disease
Radiation is a primary therapy in the treatment of thoracic malignancies with clear survival benefits. Consequently, patients with cancer are living longer but may be subject to a wide array of cardiotoxic effects from collateral radiation damage. Ensuing fibrosis can affect any portion of the cardiac parenchyma, increasing the risk for accelerated coronary artery disease, pericardial sequelae such as constrictive pericarditis, valvulopathy, restrictive cardiomyopathy, and a myriad of conduction system abnormalities. Unfortunately, the effects of cardiotoxicity can be subclinical or delayed and there remains an unmet need to standardize management strategies for these patients. Based on current data, it is prudent to consider percutaneous approaches first for coronary and valvular disease and traditional, supportive measures for the remaining sequelae. Every attempt should be made to undergo a complete operative haul due to the increased risks of re-operation if surgery is to be performed. Surrounding the patient with a multidisciplinary heart team is critical.
- Open Access
- 11 September 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (18) , 2902
Cardiac Computed Tomography Angiography in CAD Risk Stratification and Revascularization Planning
Purpose of Review: Functional stress testing is frequently used to assess for coronary artery disease (CAD) in symptomatic, stable patients with low to intermediate pretest probability. However, patients with highly vulnerable plaque may have preserved luminal patency and, consequently, a falsely negative stress test. Cardiac computed tomography angiography (CCTA) has emerged at the forefront of primary prevention screening and has excellent agency in ruling out obstructive CAD with high negative predictive value while simultaneously characterizing nonobstructive plaque for high-risk features, which invariably alters risk-stratification and pre-procedural decision making. Recent Findings: We review the literature detailing the utility of CCTA in its ability to risk-stratify patients with CAD based on calcium scoring as well as high-risk phenotypic features and to qualify the functional significance of stenotic lesions. Summary: Calcium scores ≥ 100 should prompt consideration of statin and aspirin therapy. Spotty calcifications < 3 mm, increased non-calcified plaque > 4 mm3 per mm of the vessel wall, low attenuation < 30 HU soft plaque and necrotic core with a rim of higher attenuation < 130 HU, and a positive remodeling index ratio > 1.1 all confer additive risk for acute plaque rupture when present. Elevations in the perivascular fat attenuation index > −70.1 HU are a strong predictor of all-cause mortality and can further the risk stratification of patients in the setting of a non-to-minimal plaque burden. Lastly, a CT-derived fractional flow reserve (FFRCT) < 0.75 or values from 0.76 to 0.80 in conjunction with additional risk factors is suggestive of flow-limiting disease that would benefit from invasive testing. The wealth of information available through CCTA can allow clinicians to risk-stratify patients at elevated risk for an acute ischemic event and engage in advanced revascularization planning.
- 11 September 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (18) , 2902
Open AccessCardiac Computed Tomography Angiography in CAD Risk Stratification and Revascularization Planning
Purpose of Review: Functional stress testing is frequently used to assess for coronary artery disease (CAD) in symptomatic, stable patients with low to intermediate pretest probability. However, patients with highly vulnerable plaque may have preserved luminal patency and, consequently, a falsely negative stress test. Cardiac computed tomography angiography (CCTA) has emerged at the forefront of primary prevention screening and has excellent agency in ruling out obstructive CAD with high negative predictive value while simultaneously characterizing nonobstructive plaque for high-risk features, which invariably alters risk-stratification and pre-procedural decision making. Recent Findings: We review the literature detailing the utility of CCTA in its ability to risk-stratify patients with CAD based on calcium scoring as well as high-risk phenotypic features and to qualify the functional significance of stenotic lesions. Summary: Calcium scores ≥ 100 should prompt consideration of statin and aspirin therapy. Spotty calcifications < 3 mm, increased non-calcified plaque > 4 mm3 per mm of the vessel wall, low attenuation < 30 HU soft plaque and necrotic core with a rim of higher attenuation < 130 HU, and a positive remodeling index ratio > 1.1 all confer additive risk for acute plaque rupture when present. Elevations in the perivascular fat attenuation index > −70.1 HU are a strong predictor of all-cause mortality and can further the risk stratification of patients in the setting of a non-to-minimal plaque burden. Lastly, a CT-derived fractional flow reserve (FFRCT) < 0.75 or values from 0.76 to 0.80 in conjunction with additional risk factors is suggestive of flow-limiting disease that would benefit from invasive testing. The wealth of information available through CCTA can allow clinicians to risk-stratify patients at elevated risk for an acute ischemic event and engage in advanced revascularization planning.
- 13 June 2023
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 47 (1) , 113-116
The power of three: Atrial rate limit power‐on‐reset — A non‐electromagnetic cause of pacemaker‐induced extracardiac stimulation
BackgroundPower-on reset (PoR) is most commonly due to electromagnetic interference. Full PoR results in a switch to an inhibited mode (VVI) pacing and resets pacing outputs to maximal unipolar settings, leading to extracardiac stimulation. MethodsWe present a case of PoR occurrence in the absence of electromagnetic interference, resulting in pectoral stimulation triggered by violation of the atrial rate limit. ConclusionsIt is useful for clinicians to recognizethe occurrence of PoR in the setting of atrial limit violation andthe appropriate management in such circumstances.
- 13 June 2023
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 47 (1) , 113-116
The power of three: Atrial rate limit power‐on‐reset — A non‐electromagnetic cause of pacemaker‐induced extracardiac stimulation
BackgroundPower-on reset (PoR) is most commonly due to electromagnetic interference. Full PoR results in a switch to an inhibited mode (VVI) pacing and resets pacing outputs to maximal unipolar settings, leading to extracardiac stimulation. MethodsWe present a case of PoR occurrence in the absence of electromagnetic interference, resulting in pectoral stimulation triggered by violation of the atrial rate limit. ConclusionsIt is useful for clinicians to recognizethe occurrence of PoR in the setting of atrial limit violation andthe appropriate management in such circumstances.
- 9 August 2022
- Published by Springer Nature in Current Stem Cell Reports
- Vol. 8 (4) , 164-173
Cardiovascular Imaging Databases: Building Machine Learning Algorithms for Regenerative Medicine
- 9 August 2022
- Published by Springer Nature in Current Stem Cell Reports
- Vol. 8 (4) , 164-173
Cardiovascular Imaging Databases: Building Machine Learning Algorithms for Regenerative Medicine